Press Releases Lonza Group AG Börse Stuttgart

Equities

LO3A

US54338V1017

Delayed Börse Stuttgart Other stock markets 06:29:17 2024-07-17 am EDT			5-day change	1st Jan Change
52 ^EUR	+0.97%		0.00%	+39.95%

Jul. 03	Lonza Group Names New CEO	MT
Jul. 02	Lonza Group AG Announces CEO Changes	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Lonza Welcomes New Group Chief Executive Officer Wolfgang Wienand	Jul. 01	EQ
Lonza : Q1 2024 Qualitative Update	May. 14	PU
Q1 2024 Qualitative Update: Performance In Line with Expectations for Full-Year 2024	May. 14	EQ
Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved	May. 08	EQ
Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon	Apr. 17	EQ
Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports	Apr. 03	EQ
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer	Apr. 02	EQ
Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche	Mar. 20	EQ
Jean-Marc Huët to succeed Albert M. Baehny as Chairman of Lonza	Jan. 26	EQ
Lonza Delivers Solid 2023 Performance with 10.9% CER Sales Growth and 29.8% CORE EBITDA Margin	Jan. 26	EQ
Lonza : Launches GS Effex® Cell Line for the Development of Therapeutic Antibodies with Increased Potency	Nov. 14	PU
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds	Nov. 06	EQ
Capital Markets Day 2023: New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects	23-10-17	EQ
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer	23-10-13	EQ
Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023	23-09-21	EQ
Board Announcement	23-09-18	EQ
Lonza : Half-Year 2023 Results Report	23-07-21	PU
Lonza Delivers 5.6% CER Sales Growth, With Underlying Growth at Around 10% CER and 30% CORE EBITDA Margin	23-07-21	EQ
Lonza : Launches TheraPRO® CHO Media System to Improve Productivity and Quality in Therapeutic Protein Manufacture	23-07-17	PU
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes Cell Therapies	23-06-27	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

LONZA GROUP : Some mixed real-world effects

February 06, 2024 at 10:44 am EST